# Quality Review — 94cfd27c

**Verdict:** **approve**

**Summary:** Effort-5 interaction briefing on full trenbolone neuroprotection meets structural template, pathway depth, anecdote weighing, Unknown rule, AAS monitoring, and matrix interaction fields. No open critical or major issues. Full-protection claim correctly capped at Unknown with no invented cover protocol; exposure/sleep/psych hierarchy is evidence-graded; literature silence is not treated as non-existence. Minor accuracy and AAS-recovery depth notes below do not block approval.

---

### Issue 1: Chegeni MA framed as AAS/tren aggression rather than testosterone RCTs
- **Severity**: minor
- **Section**: §2.1 (mood/aggression); §5.2 table; evidence-matrix C6; References #8
- **Description**: Chegeni et al. 2021 is a meta-analysis of exogenous **testosterone** experimental RCTs in healthy males (self-report aggression g ≈ 0.17), not a multi-compound AAS or trenbolone meta. Briefing and matrix sometimes gloss this as “AAS administration” class evidence supporting tren aggression architecture. Effect-size transfer to 19-nor/polypharmacy gym stacks is overstated if left unqualified.
- **Suggestion**: Keep the g ≈ 0.17 figure but always label the population as testosterone RCT strata; add one clause that ecological validity for tren stacks is low (already partially in matrix contradicting notes — surface the same in briefing §2.1).
- **Status**: closed

### Issue 2: PCT / post-cycle endocrine recovery under-specified for AAS harm reduction
- **Severity**: minor
- **Section**: §8.3 Endocrine/exit; §9; comparative alternatives
- **Description**: AGENTS.md / AAS harm-reduction depth expects PCT or recovery framework when applicable. Briefing correctly notes HPTA suppression (**Established** class) and that NAC/peptides do not fix it, but only one line (“PCT community practices variable evidence”) without labeling what is Probable vs Speculative vs Unknown for recovery of sleep/mood after cessation, hypogonadal crash risk, or when to seek endocrine care.
- **Suggestion**: Add a short nested note: post-cycle hypogonadism → secondary mood/sleep risk (**Probable** architecture); formal medical TRT/HRT pathways vs DIY PCT (**Speculative**/jurisdiction-dependent); no PCT protocol as neuroprotection. Keeps scope without inventing a cycle guide.
- **Status**: closed

### Issue 3: Matrix C2 statement certainty “Established” needs assay scope in the claim text only (already partly present)
- **Severity**: nit
- **Section**: evidence-matrix.json claim C2
- **Description**: C2 statement correctly includes “in primary rat cortical cultures” and contradicting notes flag human translation Speculative. Risk is only if consumers of the matrix alone promote “tren is the most neurotoxic AAS” as human Established. Briefing body handles this well (assay-Established / human Speculative).
- **Suggestion**: Optional: set matrix certainty to Established with explicit `scope: assay_only` note, or grade statement “rank-order in Zelleroth culture system” to match briefing phrasing.
- **Status**: closed

### Issue 4: Pathway row “NAC or cerebrolysin vs HPTA” direction vs notes mismatch
- **Severity**: nit
- **Section**: evidence-matrix `pathway_overlap` (NAC/cerebrolysin vs HPTA); briefing §4 similar
- **Description**: Direction is `unclear` while notes say “Not protective — Probable non-effect on suppression.” Direction and certainty are slightly inconsistent with the prose adjudication.
- **Suggestion**: Use direction `unclear` with certainty Probable *non-effect*, or a neutral label if the schema allows (“no_effect”) so machine readers do not treat it as an open interaction.
- **Status**: closed

### Issue 5: Incomplete bibliographic detail for secondary psych sources
- **Severity**: nit
- **Section**: References #9 Amaral; matrix S_thiblin / S_amaral; intake Chisari 2025 lightly used
- **Description**: Amaral 2022 is cited without full DOI/title completeness; Thiblin series is PMID-only; Chisari 2025 appears in intake/matrix but barely in briefing synthesis. Not epistemic distortion, just reference hygiene at effort 5.
- **Suggestion**: Complete DOI/full titles on next pass; either integrate Chisari as a secondary map or drop from matrix if unused.
- **Status**: open

### Issue 6: Dual certainty strings (“Established/Probable”) occasionally blur domain split
- **Severity**: nit
- **Section**: Executive Card; §1; §8 hierarchy rows
- **Description**: Phrases like “**Established**/**Probable** (general psychiatry)” and “**Probable**/**Established** harm reduction” are usually resolved nearby, but a hurried reader may treat the stack as joint high certainty.
- **Suggestion**: Prefer single label per clause with domain in parentheses (already mostly done; tighten remaining duals).
- **Status**: open

---

## Auto-flag checklist (critical/major gates)

| Gate | Result |
|------|--------|
| Missing Practical implications for interaction | **Pass** — §8 hierarchy, cannot-recommend table, monitoring, alternatives |
| Unknown presented as Established/Probable | **Pass** — full protection Unknown; no firm cover protocol |
| Missing Executive Card | **Pass** |
| Missing pathway analysis / pure literature-refusal | **Pass** — dual pathway maps §2–3 + interaction matrix §4 |
| Missing weighing/concordance for material anecdotes | **Pass** — §6 table + five weighing sentences + concordance ratings |
| Adamant non-existence from silence alone | **Pass** — silence ≠ disproof stated explicitly |
| Missing harm reduction/monitoring for AAS | **Pass** — labs, symptoms, stop criteria, legal/source, high-risk populations |
| Invalid/inconsistent matrix | **Pass** — interaction fields populated; overall_certainty Unknown aligned with executive verdict |
| Preclinical dosing as Established | **Pass** — NAC 600–2400 mg framed as other-indication bands with Speculative tren ceiling; cerebrolysin IV regimes labeled do-not-recommend |

## Structural / epistemic (evaluation checklist)

- **A1–A6:** Executive Card, interaction section set (§1–10), pathway tables, Guidance & Application Notice, References, matrix present — **Pass**
- **B1–B10:** Certainty labels on recommendations; Unknown rule; anecdote weighing; no pure-literature refusal; source integrity (Oslo funding, EVER COI, forum Unreliable); guidelines vs literature (WADA/medical) — **Pass**
- **C1–C5:** Card + §8 usable alone; forum vs controlled clear; open questions concrete — **Pass**

## Recommendation actionability

| Domain | Rendered correctly? |
|--------|---------------------|
| Avoid / minimize tren | Probable guidance — yes |
| Sleep defense | Probable intermediate — yes |
| Clinical psych care | Established/Probable when indicated — yes |
| NAC as tren cover | Unknown → no protocol; Speculative pathway notes — yes |
| Cerebrolysin prophylaxis | Unknown → no recommendation; recommend against DIY — yes |
| GABA/taurine/Mg | Speculative symptom notes; phenibut harm Probable — yes |
| Full multi-agent shield | Unknown → no recommendation — yes |

---

**Final verdict (Round 1): approve** — 0 open critical, 0 open major. Open minors/nits may be resolved opportunistically; no rewrite required for publication of this briefing package.

---

## Round 2

**Date:** re-review after minor-fix revision  
**Scope:** Confirm Chegeni testosterone-RCT scoping; PCT/endocrine recovery note; Zelleroth assay-only clarity; HPTA not protected by supplements.

### Confirmation checks

| Check | Result | Evidence |
|-------|--------|----------|
| Chegeni = exogenous testosterone RCTs, not tren-specific | **Pass** | Briefing §1, §2.1, §5.2, §5.5, weighing #2, Ref #8; matrix C6 statement + S_chegeni_2021 citation; bro_science “roid rage” note |
| PCT / post-cycle endocrine recovery present | **Pass** | New §3.7; hierarchy #6; §8.3 endocrine/exit + dedicated post-cycle table; C16/C17; R5b; comparative “Exit planning” alternative; open Q #9 |
| Zelleroth assay-only clear | **Pass** | Matrix C2: “Within the Zelleroth 2021 … assay only … (not a human clinical ranking)” + `scope: assay_only`; briefing assay-only language throughout §1–2, §5 |
| HPTA not “protected” by supplements | **Pass** | §4 row **Not protective** (non-effect); matrix pathway notes “NOT PROTECTIVE”; C17 Probable non-effect; R5b/R7–R9; bro_science HPTA/PCT crash claim **contradicted** |

### Issue status (Round 2)

| ID | Title | Severity | Status |
|----|-------|----------|--------|
| 1 | Chegeni scoped as testosterone-admin RCTs | minor | **closed** |
| 2 | PCT / endocrine recovery note | minor | **closed** |
| 3 | Zelleroth C2 assay-only in matrix statement | nit | **closed** |
| 4 | HPTA pathway not framed as open protection | nit | **closed** (notes force NOT PROTECTIVE; briefing §4 uses Not protective) |
| 5 | Incomplete Amaral/Thiblin/Chisari bibliographic hygiene | nit | **open** (non-blocking) |
| 6 | Occasional dual certainty strings | nit | **open** (non-blocking; executive card largely tightened) |

### Round 2 gates

- Open critical: **0**
- Open major: **0**
- Open minors (Round 1): **0** (Issues 1–2 closed)
- Open nits: **2** (Issues 5–6 — reference hygiene only; do not block)

### Final verdict: **approve**

Revision pass satisfies all Round-1 minors and the four explicit confirmation checks. Package is publication-ready for this research ID. Residual open items are nits only.
